Real-World Effectiveness of @entity2239 Subsequent to Different First Targeted Therapies for the Treatment of XXXX : Synthesis of Retrospective Chart Reviews.

@entity1 @entity6219 @entity2240 @entity2857 @entity2239 @entity1358
BACKGROUND: The effect of first targeted therapy on outcomes with second targeted therapy for metastatic @entity1358 is not well known. The purpose of this study was to compare outcomes for @entity1 receiving a second targeted therapy with @entity2239 by type of first targeted therapy. @entity1 AND METHODS: Data were drawn from 3 separate retrospective chart reviews conducted in 2011, 2012, and 2014. Inclusion criteria and study design were similar across the 3 studies. To be included in this analysis, @entity1 had to meet the following criteria: aged  >=  18 years; received first targeted therapy with @entity6219 , @entity2240 , or @entity2857 ; and received second targeted therapy with @entity2239 . Overall survival, time to treatment failure, and time to treatment discontinuation outcomes were measured from second targeted therapy initiation. Outcomes were compared among treatment groups by Cox proportional hazard models adjusting for demographic and clinical characteristics. Hazard ratios for overall survival, time to treatment failure, and time to treatment discontinuation obtained from the 3 chart reviews were synthesized in meta-analyses. RESULTS: Of 696 @entity1 treated with @entity2239 as second targeted therapy, 605 @entity1 received first targeted therapy with @entity2240 / @entity2857 and 91 with @entity6219 . After synthesizing the hazard ratios from all studies in meta-analyses, there were no significant differences in study outcomes between @entity1 receiving @entity2240 / @entity2857 versus those receiving @entity6219 as first targeted therapy. CONCLUSION: There were no significant differences among outcomes while receiving second targeted therapy with @entity2239 for @entity1 treated with @entity6219 versus @entity2240 / @entity2857 as first targeted therapy.
